AstraZeneca's DKD pipeline highlights potential to different

In a recent quarterly update, AstraZeneca revealed that it removed tozorakimab from its phase 2 pipeline for diabetic kidney disease (DKD).

Related Keywords

Kajal Jaddoo , Astrazeneca , , Markets Amp Regulations , Bio Developments , Pipelines , Emerging Markets , Kidney Disease , Diabetes , Pharmaceutical Industry ,